Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02623972 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
A Phase 2 study of Inflammatory Breast Cancer and Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 2
- Study locations
NCT02623972: Active Phase 2 study of Inflammatory Breast Cancer and Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, sponsored by Dana-Farber Cancer Institute.
NCT02623972 is a Phase 2 study of Inflammatory Breast Cancer and Human Epidermal Growth Factor 2 Negative Carcinoma of Breast that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 22 participants, below the 90-participant average among 5 other Inflammatory Breast Cancer trials with a reported enrollment target (76% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02623972, a Phase 2 study of Inflammatory Breast Cancer and Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is studying a drug called eribulin combined with standard treatment as a possible preoperative treatment for HER2 negative inflammatory breast cancer.
Primary Outcome
Complete pathologic disease response (pCR) is defined as absence of invasive carcinoma within the breast and axillary lymph nodes following preoperative therapy, based upon pathological assessment of surgical specimens. Those with invasive carcinoma present within the breast and axillary lymph nodes, and participants whose disease is not surgically resectable following preoperative treatment are considered as not having pCR.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Eribulin
- DRUG Adriamycin
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-02-26 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT02623972 still lists
NCT02623972 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 90-participant average among 5 other Inflammatory Breast Cancer trials with a reported enrollment target (76% lower).
The record links to 2 conditions, with Inflammatory Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT02623972 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02623972 about?
NCT02623972 is a clinical study titled "A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer". This research study is studying a drug called eribulin combined with standard treatment as a possible preoperative treatment for HER2 negative inflammatory breast cancer.
What is the current status of trial NCT02623972?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2016-02-26. Estimated completion is 2026-12.
What conditions does trial NCT02623972 study?
This clinical trial studies the following conditions: Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast.
What interventions are being tested in trial NCT02623972?
The interventions under investigation include: Cyclophosphamide (DRUG), Eribulin (DRUG), Adriamycin (DRUG).
Who is sponsoring clinical trial NCT02623972?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02623972 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammatory Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
COMPLETED · Phase 2
-
Refining Local-Regional Therapy for IBC
RECRUITING · NA
-
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
RECRUITING · NA
-
Onvansertib + Paclitaxel In TNBC
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI